Product Details
| Product Name:
Aramchol |
CAS No.:
246529-22-6 |
| Purity:
≥95% |
Supply Ability:
10g |
| Release date:
2025/10/22 |
Product Introduction
Bioactivity
| Name | Aramchol |
| Description | Aramchol (C20-FABAC), also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid. It reduces ex vivo cholesterol crystallization in native human bile and dissolves pre-formed cholesterol crystals in a dose-dependent manner. |
| Animal Research | Performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n = 20/group). The main end point was the difference between groups in the change in liver fat content according to magnetic resonance spectroscopy. The secondary end points focused on the differences between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function[1]. |
| In vivo | Three months' administration of the fatty acid-bile acid conjugate Aramchol is significantly reduces liver fat content in patients with NAFLD. The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 53.33 mg/mL (75.96 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Aramchol |
| Inhibitors Related | Elemicin | PluriSIn 1 | CVT-11127 | SLC13A5-IN-1 | CAY10566 | MF-438 | MK-8245 analog | A939572 | XEN723 | SCD1 inhibitor-4 | GSK1940029 | YTX-465 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Fibrosis Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:82413-20-5
$49.00 / 1mg
-
CAS:212631-67-9
$32.00 / 1mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States